Champions Oncology, Inc. - Common Stock (CSBR)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Mar 27, 2026Investment Snapshot
- Trading 307% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 94.5% — good return on equity
- Revenue growing at 14% annually
Champions Oncology, Inc. - Common Stock (CSBR) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $80 million . Key value metrics: P/E ratio 19.9, P/B ratio 18.77, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Champions Oncology, Inc. - Common Stock — Fundamental Analysis Summary
Champions Oncology, Inc. - Common Stock (CSBR) is currently trading 307% above its Graham Number of $1.42, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 19.9x.
On financial health, CSBR shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 94.5% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 6.22.
StockPik's composite Value Score for CSBR is 72/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CSBR reports a solid gross margin of 51.0% (sector average: 33.5%) and a modest operating margin of 6.2%.
CSBR shows revenue growing at 14% year-over-year, with earnings growing at 165%.